Specifically, a mechanistic understanding of how CD103+ DCs sense epithelial cell ER stress to trigger IL-23 and shape inflammatory Th17 cell responses has the potential to impact therapeutic approaches for IBD. This evidence concerns the gene IL37 and inflammatory bowel disease.